Arachidonic acid prevents hyperglycemia-associated yolk sac damage and embryopathy.
Light microscopic, electron microscopic, and morphometric studies were performed on rat conceptuses cultured between day 10 and day 12 in normal, hyperglycemic, arachidonic acid-supplemented normal, and arachidonic acid-supplemented hyperglycemic rat serum. The results were compared with those of 12-day-old conceptuses grown in utero. No major differences were observed between in vivo and in vitro control conceptuses. Arachidonic acid supplementation of control culture medium resulted in an improvement of conceptus development. Addition of 20 micrograms/ml of arachidonic acid to an otherwise teratogenic hyperglycemic serum medium (950 mg/dl of D-glucose) prevented the malformations induced by hyperglycemic conditions: open neural tube, advanced neuropil formation in the neuroepithelium, significant reduction of rough endoplasmic reticulum, decreased size and number of lipid droplets, and increased number of lysosome-like structures in the visceral endodermal yolk sac cells.
D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology*; D001786:Blood Glucose / Q000502:physiology*; D000013:Congenital Abnormalities / Q000209:etiology / Q000517:prevention & control*; D004707:Endoderm / Q000648:ultrastructure; D005260:Female; D006943:Hyperglycemia / Q000150:complications*; D066298:In Vitro Techniques; D008297:Male; D011247:Pregnancy; D051381:Rats; D013116:Spinal Cord / Q000187:drug effects / Q000196:embryology; D014781:Viscera / Q000187:drug effects / Q000196:embryology; D015017:Yolk Sac / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure
D001095:Arachidonic Acids; D001786:Blood Glucose; D016718:Arachidonic Acid